Upstate Clinical Research   Report issue

For profit Phase 2 Phase 3
Founded: Williamsville NY United States (1999)

Organization Overview

First Clinical Trial
2005
NCT00109161
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Upstate Clinical Research, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

dalfampridine (ampyra) (1 trial)

Drugs in Phase 2 Trials (1)

daclizumab (Zenapax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2